A Pivotal Phase II study of Resiniferatoxin for the Treatment of Cancer Pain
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
Price : $35 *
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- Sponsors Sorrento Therapeutics
- 04 Jan 2019 According to a Sorrento Therapeutics media release, Resiniferatoxin is expected to move into pivotal trials in 2019.
- 08 Aug 2016 According to a Scintilla Pharmaceuticals media release, this study is expected to initiate in early 2017.
- 20 May 2014 New trial record